Actinic Keratosis Epidemiology Research Insights

    73
    0
    SHARE
    Alopecia

    DelveInsight’s “Actinic Keratosis – Epidemiology Insights, 2023” report provides an overview of the disease of the Actinic Keratosis for the United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. It also includes historical and forecasted epidemiological data for the prevalent cases of Actinic Keratosis from 2013-2023.
    Actinic Keratosis (AK) commonly known as a solar keratosis is a precancerous crusty lesion caused by damage from exposure to ultraviolet (UV) radiation. It is considered a pre-cancer condition if left untreated could develop into a skin cancer, most often squamous cell carcinoma (SCC). AKs appear on areas which are most commonly exposed to sun such as the face, scalp, shoulders, neck, the back of the hands and forearms, etc.
    The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.

    Scope
    The report provides historical as well as forecasted epidemiology of Actinic Keratosis in the 7MM.
    Report covers the disease overview including pathophysiology, symptoms, diagnosis, disease management, and current treatment options.

    Request for a Demo or Sample Copy of Report at: https://www.diligentmarket.com/request-sample-page.php?gturl=13792

    Scope of this report: The report provides competitive Epidemiology landscape of Actinic Keratosis. The report provides the marketed drugs information including its sales, development activities and details of patent expiry. The report provides the insight of current and future market for Actinic Keratosis. The report provides Epidemiology products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information. Coverage of the Actinic Keratosis Epidemiology on the basis of target, MOA, route of administration, technology involved and molecule type. The report reviews key players involved in the therapeutics development for Actinic Keratosis and also provide company profiling. The report also gives the information of dormant Epidemiology projects. Epidemiology products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages and Provides Epidemiology assessment by monotherapy and combination therapy products, stage of development and molecule type.

    List of Table

    Table 1: Prevalent and Treatable Population of Actinic Keratosis in United States (2013-2023)
    Table 2: Prevalent and Treatable Population of Actinic Keratosis in Germany (2013-2023)
    Table 3: Prevalent and Treatable Population of Actinic Keratosis in France (2013-2023)
    Table 4: Prevalent and Treatable Population of Actinic Keratosis in United Kingdom (2013-2023)
    Table 5: Prevalent and Treatable Population of Actinic Keratosis in Italy (2013-2023)
    Table 6: Prevalent and Treatable Population of Actinic Keratosis in Spain (2013-2023)
    Table 7: Prevalent and Treatable Population of Actinic Keratosis in Japan(2013-2023)

    Browse Full Report at: https://www.diligentmarket.com/actinic-keratosis-epidemiology-forecast-to-2023-13792-p.php

    List of Figures

    Figure 1: Prevalent and Treatable Population of Actinic Keratosis in United States (2013-2023)
    Figure 2: Prevalent and Treatable Population of Actinic Keratosis in Germany (2013-2023)
    Figure 3: Prevalent and Treatable Population of Actinic Keratosis in Italy (2013-2023)
    Figure 4: Prevalent and Treatable Population of Actinic Keratosis in Spain (2013-2023)
    Figure 5: Prevalent and Treatable Population of Actinic Keratosis in France (2013-2023)
    Figure 6: Prevalent and Treatable Population of Actinic Keratosis in United Kingdom (2013-2023)
    Figure 7: Prevalent and Treatable Population of Actinic Keratosis in Japan (2013-2023)
    Figure 8: IngenolDisoxate, Clinical Trials by Zone, 2017
    Figure 9:Clinical Trials by Recruitment status, 2017
    Figure 10: Number of Products under development by Companies, 2017
    Figure 11: Clinical Stage Products, 2017
    Figure 12: Pre-Clinical Stage Products, 2017
    Figure 13: Assessment by Monotherapy Products, 2017
    Figure 14: Assessment by Combination Products, 2017
    Figure 15: Assessment by Route Of Administration, 2017
    Figure 16: Assessment by Stage and Route Of Administration, 2017
    Figure 17: Assessment by Molecule Type, 2017
    Figure 18: Assessment by Stage and Molecule Type, 2017
    Figure 19: Assessment by Stage of development and Domain, 2017
    Figure 20: Assessment by Stage of development and Domain, 2017
    Figure 21: Total Market size of Actinic Keratosis in USD Million (2013-2023)
    Figure 22: United States Market Size of Actinic Keratosis in USD, Million (2013-2023)
    Figure 23: Germany Market Size of Actinic Keratosis in USD, Million (2013-2023)
    Figure 24: Italy Market Size of Actinic Keratosis in USD, Million (2013-2023)
    Figure 25: Spain Market Size of Actinic Keratosis in USD, Million (2013-2023)
    Figure 26: France Market Size of Actinic Keratosis in USD, Million (2013-2023)
    Figure 27: United Kingdom Market Size of Actinic Keratosis in USD, Million (2013-2023)
    Figure 28:Japan Market Size of Actinic Keratosis in USD, Million (2013-2023)

    About us:

    DiligentMarket is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. We support companies by providing end to end comprehensive solutions to improve their performance and in making long lasting decision for their businesses.

    We advise leading decision makers on their critical issues and opportunities; Research & Development, Strategy Making, Commercial, Operations, Competitive Intelligence, Competitive Landscaping and Mergers & Acquisition across all the Pharma and Biotech industries and geographies. We serve our clients by delivering practical and enduring results, and equipping our clients to grow and lead.

    The pharmaceuticals market is in its growth stage and we are uniquely positioned to successfully endeavor the dimensions of the fast growing market by providing cutting-edge market and Epidemiology information, to our clients.

    Connect With us on:

    +91-750 707 8687

    sales@diligentmarket.com

    LEAVE A REPLY

    Please enter your comment!
    Please enter your name here